Search research articles
Contact Us
Filters
Showing results (111-120 of 126) with videos related to
Page
of 13
Sort By:
Vaccine
|
June 6, 2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea
Yap Boum, Aitana Juan-Giner, Matt Hitchings, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever
Vanessa N Raabe, Gerrit Kann, Bruce S Ribner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 1, 2019
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
Chris Davis, Tom Tipton, Suleman Sabir, et al.
Journal of Virology
|
September 16, 2024
Distinct negative-sense RNA viruses induce a common set of transcripts encoding proteins forming an extensive network
Nina Hofmann, Marek Bartkuhn, Stephan Becker, et al.
Journal of the American College of Cardiology
|
October 15, 2011
Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial
Urs Benck, Simone Hoeger, Paul T Brinkkoetter, et al.
Plos Medicine
|
October 7, 2017
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
Selidji T Agnandji, José F Fernandes, Emmanuel B Bache, et al.
Cell Host & Microbe
|
November 18, 2022
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
Philip J M Brouwer, Aleksandar Antanasijevic, Adam J Ronk, et al.
Science Translational Medicine
|
May 17, 2013
Synthetic generation of influenza vaccine viruses for rapid response to pandemics
Philip R Dormitzer, Pirada Suphaphiphat, Daniel G Gibson, et al.
BMC Medicine
|
November 7, 2024
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)
Conall H Watson, Pierre-Stéphane Gsell, Yper Hall, et al.
Emerging Infectious Diseases
|
February 21, 2018
New Lineage of Lassa Virus, Togo, 2016
Shannon L M Whitmer, Thomas Strecker, Daniel Cadar, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 126) with videos related to
Sort By:
Page
of 13
Vaccine
|
June 6, 2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea
Yap Boum, Aitana Juan-Giner, Matt Hitchings, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever
Vanessa N Raabe, Gerrit Kann, Bruce S Ribner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 1, 2019
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
Chris Davis, Tom Tipton, Suleman Sabir, et al.
Journal of Virology
|
September 16, 2024
Distinct negative-sense RNA viruses induce a common set of transcripts encoding proteins forming an extensive network
Nina Hofmann, Marek Bartkuhn, Stephan Becker, et al.
Journal of the American College of Cardiology
|
October 15, 2011
Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial
Urs Benck, Simone Hoeger, Paul T Brinkkoetter, et al.
Plos Medicine
|
October 7, 2017
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
Selidji T Agnandji, José F Fernandes, Emmanuel B Bache, et al.
Cell Host & Microbe
|
November 18, 2022
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
Philip J M Brouwer, Aleksandar Antanasijevic, Adam J Ronk, et al.
Science Translational Medicine
|
May 17, 2013
Synthetic generation of influenza vaccine viruses for rapid response to pandemics
Philip R Dormitzer, Pirada Suphaphiphat, Daniel G Gibson, et al.
BMC Medicine
|
November 7, 2024
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)
Conall H Watson, Pierre-Stéphane Gsell, Yper Hall, et al.
Emerging Infectious Diseases
|
February 21, 2018
New Lineage of Lassa Virus, Togo, 2016
Shannon L M Whitmer, Thomas Strecker, Daniel Cadar, et al.
Page
of 13